
    
      This study was designed as an open-lable, single-arm, exploratory clinical study. Sintilimab
      in combination with liposome paclitaxel, cis-platinum and S-1 will be given every 3 weeks to
      our patients for 2 cycles as neoadjuvant therapy. A radical dissection is scheduled within 6
      weeks after last neoadjuvant treatment. This study will be devided for 3 phases: safety
      run-in, efficacy pilot and efficacy confirmation.
    
  